The Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health (CADTH) are pleased to jointly launch the recruitment process for a Health Technology Assessment (HTA) Patient Engagement Navigator to assist patient groups in understanding the HTA landscape and to provide patient groups with the support required to help optimize the patient submission for cancer drugs under review by pCODR, as well as develop, identify and support opportunities for patient and caregiver involvement relating to the pCODR program.
A key member of a dedicated HTA team comprised of project advisory members, content experts, partners and key stakeholders, this dynamic role will support collaborative efforts to enhance patient engagement, transparency and collaboration in the health technology assessment of new cancer drugs in Canada.
Based in downtown Toronto, the HTA Patient Engagement Navigator is a temporary, full-time position responsible for linking the Canadian cancer patient community to the HTA drug review process prior to a manufacturer or tumour group making a submission to pCODR for review, as well as after funding recommendations are issued by pCODR’s Expert Review Committee. The HTA Patient Engagement Navigator will work closely with the patient community, as well as key project stakeholders to help construct a sustainable, multi-faceted HTA Patient Engagement Model in Canada.
Funded by the Canadian Partnership Against Cancer (the Partnership), with in-kind funding provided by CADTH and CCAN, this exciting project reflects a shared commitment to addressing the expressed needs of patient groups in Canada. We believe that patient engagement and input on drug reviews is important to the HTA process as it ensures patients’ and caregivers’ experiences of living with the condition and undergoing treatment are routinely considered.
The deadline date for applications is May 25, 2016 with an anticipated start date of no later than June 27, 2016.
To learn more about this role: http://www.ccanceraction.ca/wp-content/uploads/2016/05/2-0-FINAL-HTA-Job-Description.pdf
To view the job posting: http://www.ccanceraction.ca/wp-content/uploads/2016/05/2-0-FINAL-HTA-Posting.pdf
To apply in confidence: firstname.lastname@example.org
Founded in 2001, CCAN is a national patient-centred umbrella organization working closely with patient advocacy groups and other key cancer control stakeholders across Canada. With a membership expansion rate of more than 200% in the last three years, the organization engages 114 diverse member organizations to embed an informed and coordinated patient and caregiver perspective in defined areas of priority or interest to the community. CADTH’s pan-Canadian Oncology Drug Review is an evidence-based, cancer drug review process designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness and patient perspectives in order to provide funding recommendations to Provinces and Territories and cancer agencies. The HTA Patient Engagement Navigator initiative is funded by the Canadian Partnership Against Cancer with in-kind funding provided by CADTH and CCAN.